140 results about "Prostatic Cancers" patented technology

The invention relates to the technical field of artificial intelligence, and discloses a prostate cancer early screening model construction method based on deep learning. The method comprises the following steps: acquiring a multi-modal magnetic resonance imaging data set; segmenting the positive focus and encoding the positive focus into pathological state vectors; constructing a conditional generative adversarial network under pathological state constraints to generate a synthetic focus image with specified pathological features; seamlessly embedding the synthetic focus into a healthy background through a gradient domain fusion algorithm to generate a high-reality positive sample; and integrating the original and synthetic samples to train a three-dimensional convolutional neural network screening model. The system comprises a multi-modal image acquisition module, a pathological feature vectorization module, a condition generation module, a focus fusion module and a model training deployment module. According to the method, the model generalization ability and the early screening accuracy are remarkably improved, and the missed diagnosis rate is effectively reduced.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention discloses a double-target chimeric antigen receptor capable of simultaneously targeting TLL1 and B7H3, a CAR-T cell and application of the double-target chimeric antigen receptor. The chimeric antigen receptor is a fusion protein which is sequentially composed of Omburt-scFv (SEQ ID NO: 1) targeting B7H3, a CD8 alpha hinge region and transmembrane region, a 4-1BB costimulatory domain, a CD3 zeta signal domain and TLL1-scFv (SEQ ID NO: 6) targeting TLL1 from an N terminal to a C terminal. The TLL1-scFv can be efficiently combined with TLL1 protein, can inhibit a TGF-beta signal channel and block prostate cancer cell migration, and is integrated into CAR of targeted B7H3, so that the double-target CAR-T cell with direct killing and immune microenvironment regulation functions is successfully constructed. The CAR-T cell has a remarkable killing effect on a prostate cancer cell line DU145, can be strongly activated after being co-cultured with a target cell and secretes a large amount of IFN-gamma and TNF-alpha, and shows high immunocompetence. The invention provides a new synergistic immunotherapy strategy for the B7H3-positive prostate cancer with the TGF-beta signal channel activated.

The invention specifically discloses application of VGF as a diagnostic biomarker for prostatic cancer, and relates to the technical field of biological medicines. The secretory protein VGF is identified to be remarkably up-regulated in prostatic fluid of a prostatic cancer patient before puncture for the first time, high expression of the secretory protein VGF is proved to be independently related to shorter progression-free lifetime and total lifetime through a public database, and a brand-new liquid biopsy marker is provided for PCa non-invasive early screening and prognosis evaluation.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

Disclosed herein are methods including LATS kinase inhibitors or TIP60 inhibitors to perturb lineages within heterogenous tumors (e.g., prostate cancer) and enhance responsiveness to Androgen Receptor Signaling Inhibitor (ARSI) therapy or other therapeutic agents that target adenocarcinoma lineages (e.g., PSMA or STEAP1-expressing tumor cells.

The present disclosure provides methods for treating prostate cancer patients with an anti-STEAP1 antigen-binding protein such as xaluritamig either as monotherapy or in combination with another therapeutic agent.

Methods of treating prostate cancer, including castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, comprising administering an effective amount of an androgen receptor (AR) antagonist and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator (SGRM) are disclosed. The AR antagonist may be enzalutamide. The SGRM may be an octahydro fused azadecalin compound, such as exicorilant, ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-methyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone which has the structure: The AR antagonist and the SGRM may be administered once per day, and may be administered with food. Enzalutamide doses may be 150-200 mg / day, e.g., 160 mg / day. Exicorilant doses may be 100-350 mg / day, e.g., 240 mg / day, or 280 mg / day, or 320 mg / day.

Systems and methods for evaluating progression of an anatomical object over a plurality of timepoints are provided. Longitudinal medical images of an anatomical object of a patient acquired over a plurality of timepoints are received. For each respective timepoint of the plurality of timepoints, features are extracted from the longitudinal medical images acquired at the respective timepoint using a machine learning based feature extractor network and the anatomical object in the longitudinal medical images acquired at the respective timepoint is analyzed based on the extracted features using a machine learning based prediction model. Progression of the anatomical object over the plurality of timepoints is evaluated based on results of the analyses using a machine learning based progression model. The evaluation of the progression of the anatomical object over the plurality of timepoints is output.

The application discloses a prostate cancer bone metastasis risk prediction diagnosis device and relates to the technical field of prostate cancer diagnosis. The application comprises a diagnosis table, two support rods are symmetrically arranged on one side of the diagnosis table, support plates are arranged on the sides of the two support rods away from each other, an adjusting assembly for adjusting the positions of the support plates is arranged on the support rods, a connecting block is fixed at one end of the diagnosis table, a movable groove is arranged in the connecting block, movable blocks are fixed at the bottom ends of the support rods, and the movable blocks are slidably connected in the movable groove. When rectal digital examination is needed for a patient, the patient is laid on the diagnosis table, the bent parts of the legs of the patient are respectively arranged on the two support plates, the two movable blocks are driven to move away from each other through a driving mechanism, the legs of the patient are bent and separated, and the patient is in a supine position, so that rectal digital examination in a supine position is facilitated.

The application discloses a prostate cancer patient pelvic floor muscle recovery evaluation system based on artificial intelligence, which comprises an original data collection module, an original data optimization module, a time sequence double-end recovery evaluation model establishment module, a recovery evaluation model performance optimization module and a whole-cycle intelligent recovery evaluation module. The application relates to the technical field of medical data processing, in particular to a prostate cancer patient pelvic floor muscle recovery evaluation system based on artificial intelligence. The scheme innovatively proposes a time sequence double-end recovery evaluation model combining an in-hospital baseline end and a home continuous time sequence end, improves the real-time performance of patient pelvic floor muscle recovery evaluation, extracts short-term time sequence recovery features by using a bidirectional long short-term memory network, extracts long-term time sequence recovery features by combining an improved convolution residual network with a parallel activation function, significantly improves the accuracy of the recovery evaluation results, and introduces an improved optimization algorithm combined with a dynamic local search strategy, thereby significantly improving the stability and accuracy of the output results of the model.

The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

Methods of treating non-metastatic castration-resistant prostate cancer in a subject having severe liver damage are provided.SOLUTION: Provided are methods of treating non-metastatic castration-resistant prostate cancer in a subject with severe hepatic impairment with an androgen receptor inhibitor comprising 4 - [7 - (6-cyano-5-trifluoromethylpyridin-3-yl) - 8-oxo-6-thioxo-5, 7-diazaspiro [3.4] oct-5-yl] - 2-fluoro-N-methylbenzamide (apalutamide).SELECTED DRAWING: None

The application discloses a kit for predicting the curative effect of immunotherapy on prostate cancer patients, which comprises reagent A, reagent B, reagent C, reagent D, reagent E and reagent F; the reagent A is a PBS buffer solution; the reagent B is a lymphocyte separation medium; the reagent C is a red blood cell lysis solution; the reagent D is a cell surface CD3 flow antibody; the reagent E is a cell surface CD19 flow antibody; and the reagent F is a 1% polyformaldehyde solution in terms of mass percentage concentration. The application further discloses an application method of the kit, which comprises the following steps: collecting venous blood of prostate cancer patients; extracting peripheral blood mononuclear cells (PBMC) in the venous blood of the prostate cancer patients; incubating the flow antibody; and performing flow cytometry analysis. The kit and the application thereof are simple and fast, non-invasive, repeatable, low in cost and short in detection time.

This is a method for treating prostate cancer. Specifically, it involves the use of the compound shown in Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a drug for treating metastatic castration-resistant prostate cancer. [Formula 1] JPEG2026521901000005.jpg32155

Prodrugs of testosterone and their use in alleviating, improving or reducing a risk of developing one or more conditions associated with androgen deprivation therapy (ADT), including orchiectomy or administration of a luteinizing hormone-releasing hormone agonist / antagonist, for the treatment of prostate cancer, including metastatic prostate cancer. In some aspects the prodrugs can be administered intranasally to target the central nervous system.

The present invention pertains to a multiple biomarker for cancer diagnosis and a use thereof and, specifically, to a composition for cancer diagnosis, comprising an agent for measuring the protein or mRNA expression levels of IGFI, KLK2, PKCα, and TRPM8. The present inventors confirmed that rapid and accurate cancer diagnosis can be performed by detecting the unique marker combination of IGFI, KLK2, PKCα, and TRPM8 of the present invention in serum samples from actual cancer patients and one or more cancers can be simultaneously detected. Thus, the combination of IGFI, KLK2, PKCα, and TRPM8 is expected to allow for the rapid and accurate diagnosis of various cancers including prostate cancer.

The invention relates to an application of NUDT14 in improving the sensitivity of Enzalocamide to prostatic cancer treatment. Through deep research, it is clear that NUDT14 can be used as a key factor for occurrence and development of prostate cancer and generation of enzalocamide treatment drug resistance, activities such as proliferation and metastasis of prostate cancer can be obviously inhibited by inhibiting NUDT14 or reducing the biological activity of NUDT14, the drug resistance of enzalocamide is reversed, the treatment sensitivity of enzalocamide is improved, and the survival rate of patients is prolonged; the prognosis is improved. According to the invention, related mechanisms of drug resistance generation and regulation in the process of treating prostatic cancer by enzalocamide are enriched, sufficient scientific basis and theoretical basis are provided for searching new prostatic cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, accurate treatment can be better realized, and the application of enzalocamide in treatment of prostatic cancer is promoted. The method has important social value and scientific significance.

The present disclosure relates to ureido ligands targeting PSMA comprising a moiety targeting PSMA, a linker, and a pyridazine moiety. The disclosed PSMA-targeted ureido ligands are suitable for use as radiopharmaceuticals, as imaging agents (e.g., diagnostic agents), or for the treatment of prostate cancer, or as diagnostic agents.

A kind of ethenyl indole and medium ring compound and its synthesis method, compound includes axial chiral ethenyl indole and nine-membered ring compound and ethenyl indole and eight-membered ring compound, structural formula is as shown in formula 3 and formula 6 respectively;Synthesis method: with formula 1 compound 3-ethynyl-2-indole methanol and formula 2 compound 2-indole ethanol / formula 5 compound 2-indole methanol as reaction raw material is added to organic solvent, additive is added, under the catalysis of catalyst and under certain temperature condition stirring reaction, TLC is tracked to complete reaction, filter, concentrate, purify and obtain.The ethenyl indole and medium ring compound synthesized in the application, through biological activity test, shows that the two types of derivatives have high sensitivity and strong cytotoxic activity to human prostate cancer cell PC-3.The reaction condition of the application is relatively conventional, the reaction process is mild, simple, low in cost, suitable for industrial large-scale production, and the application range of the method is widened.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

The invention discloses a prostate cancer image classification method based on axial consistency enhancement and threshold guide selection, and the method comprises the steps: designing an axial consistency context enhancement module ACE, combining strip pooling with axial self-attention, and enhancing the correlation expression between different spatial positions in a feature map through explicit modeling cross-row / cross-column long-distance structural dependence; a threshold guide semantic selection module TGSS is proposed to fuse horizontal, vertical and channel three-view weight information, differential processing of foreground focus enhancement and background tissue reconstruction is realized through hard threshold segmentation, and morphological gradient modeling is performed on a boundary transition region. Compared with the prior art, the method can further improve the precision of the algorithm model on related tasks of prostate cancer image classification.

A computer system that analyzes medical-imaging data to assess a risk for prostate cancer is described. The computer system may compute features (including intensity, texture and / or spatial features) based at least in part on the medical-imaging data. Then, using a pretrained predictive model, the computer system may determine cancer predictions on a voxel-by-voxel basis, based at least in part on the computed features. Note that the pretrained predictive model may include a boosted parallel random forests (BPRF) model with a boosted ensemble of bagging ensemble models, where a given bagging ensemble model includes an ensemble of random forests models. Next, the computer system may provide feedback based on the cancer predictions for the voxels. For a given voxel, the feedback may include a cancer prediction and a location. In some embodiments, for the given voxel, the feedback may include an aggressiveness of the predicted cancer and / or a recommended therapy.

The invention provides a prostate cancer multi-target joint detection kit, a detection system and application, multiple targets in the kit are selected from an MSMB gene, an AMACR gene, a PCGEM1 gene, an MALAT1 gene and an MIR4435 gene, and the kit further comprises a primer and probe combination aiming at each marker. According to the method, the diagnosis accuracy can be improved, the weight interpretation model can be constructed, the clinical decision can be optimized, and a non-invasive and high-compliance auxiliary diagnosis tool is provided for the problems of traumatic detection and gray areas in the prior art.

The invention relates to the technical field of medical health data processing, and discloses a prostate cancer accurate diagnosis and treatment decision support system based on a knowledge graph, which comprises a multi-modal data acquisition module, a semantic alignment reasoning module and a decision link construction module, and is characterized in that prostate specific antigens, image scores, puncture grading and gene data are called by the system; a time phase difference between biochemical metabolism transient change and structure lag response is utilized to construct a multi-mode heterogeneous topological graph, a phase translation compensation representation vector is generated through a mapping operator, a decision link construction module determines node association weight, a deduction sub-graph reflecting disease evolution state is generated by utilizing path search, and the decision link construction module determines a decision link. According to the method, cross-modal time-phase deviation compensation logic is utilized, observation asynchronism is eliminated, early-stage small metastasis characteristics of tumors are captured, and the auditing performance of diagnosis and treatment decisions is improved.

This utility model discloses a prostate cancer imaging device based on nuclear medicine imaging, comprising: a base, a bed board disposed on top of the base, and an imaging mechanism disposed on top of the bed board; a tilt adjustment component is disposed between the base and the bed board; the tilt adjustment component includes: a semi-cylinder fixed to the top of the base, and a semi-worm gear fixed to the top of the semi-cylinder. By disposing of the tilt adjustment component between the base and the bed board, when the patient lies on the bed board and the imaging posture needs to change at a certain angle from the supine posture, the bed board can be tilted relative to the base at a certain angle through the cooperation of a first servo motor, a worm gear, a semi-worm gear, several swing blocks, a limiting groove, several fixing rings, and limiting components. This eliminates the need for the patient to adjust their supine posture to achieve the required imaging posture, while also providing convenience for patients with limited mobility, thereby improving the practicality of the device.

The invention discloses a molecular classification diagnosis system for diagnosing prostatic cancer through a multi-target combined weight system, and belongs to the technical field of biological medicine. The method comprises the following steps: establishing a mathematical logic relationship among multiple targets through data training by utilizing an existing clinical database containing information of patients with prostatic cancer and benign hyperplasia, namely, a weight ratio of four biomarkers related to prostatic cancer to diagnosis of prostatic cancer, and obtaining a weight diagnosis formula for classification of prostatic cancer and benign hyperplasia of prostatic; a weight detection system is established, a DNA tetrahedral framework nucleic acid dimer structure is used as a signal output substrate, and a multi-target combined intelligent diagnosis system is constructed by pricing and modifying different signal molecules on a signal output probe, so that precise classification of prostatic cancer and benign prostatic hyperplasia is realized, and the accuracy of early diagnosis of prostatic cancer is improved.

The invention discloses a prostate cancer patient follow-up visit system and method integrating intestinal health management, and belongs to the technical field of medical information. The invention provides a follow-up visit system integrated with intestinal health management in order to overcome the defects that existing follow-up visit of prostate cancer only pays attention to tumor indexes, lacks intestinal micro-ecological monitoring and is low in efficiency and intervention aging due to one-step operation. The system is composed of a patient data acquisition module, an intestinal health assessment module, a follow-up visit planning and reminding module, an individual intervention suggestion module and a data analysis and feedback module. A hospital information system interface and a patient terminal are used for collaborative collection, an evaluation module and plans / prompts are linked to generate a dynamic follow-up visit, intervention suggestions and a data analysis closed-loop optimization scheme, and illness state and intestinal tract two-dimensional monitoring, individual intervention and continuous optimization are achieved.